Morgan Stanley initiated coverage on Novo Nordisk A/S
$NVO
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley initiated coverage of Novo Nordisk A/S with a rating of Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $64.00 | Outperform → Market Perform | BMO Capital Markets |
| 3/13/2025 | Hold → Buy | Kepler | |
| 3/3/2025 | Buy → Hold | Stifel | |
| 2/12/2025 | Equal-Weight | Morgan Stanley | |
| 1/6/2025 | Underperform → Mkt Perform | Bernstein | |
| 5/30/2024 | $156.00 | Buy | Goldman |
| 4/12/2024 | $163.00 | Outperform | BMO Capital Markets |
| 1/23/2024 | $120.00 | Overweight | Morgan Stanley |
BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00
Kepler upgraded Novo Nordisk A/S from Hold to Buy
Stifel downgraded Novo Nordisk A/S from Buy to Hold